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In 1967, Chou described the presence of cytoplasmic and nuclear aggregates of paramyxo-
virus nucleocapsid-like filamentous structures on electron microscopy (EM) in a 66-year 
old man with a steroid-resistant “chronic polymyositis”.1 In 1970 Carpenter et al. reported 
a case with cytoplasmic bodies and vacuoles,2 frequently rimmed with basophilic granules 
and a few also containing homogeneous eosinophilic structures on light microscopy (LM) 
and with a similar EM muscle pathology as the patient described earlier by Chou.1 Subse-
quently, Yunis and Samaha in 1971 published their observation of nuclear inclusions in a 
28-year old woman with “chronic myositis”.3 They also detected cytoplasmic eosinophilic 
inclusions by LM and filaments by EM. After having compared them with the already pub-
lished similar cases they introduced the term “inclusion body myositis” (IBM).
In 1978 following the publication of a few other case reports Carpenter et al. added six 
cases of their own and defined distinct clinical and histological hallmarks in 14 patients,4 
using the name proposed by Yunis and Samaha. These hallmarks were: male predomi-
nance, occurrence with advanced age, slowly progressive and usually painless muscle 
weakness, distal muscle involvement greater than or equal to that of proximal muscles, 
no association with malignancy, neuropathic traits at clinical examination and by elec-
tromyography, normal or mildly elevated serum creatine kinase activity (sCK), cortico-
steroid resistance and as the most essential finding basophilic granules lining vacuoles 
in hematoxylin and eosin-stained cryostat sections that curiously dissolved in paraffin 
sections. They discussed the differences with other inflammatory myopathies and con-
sidered IBM a distinct variety of the idiopathic inflammatory myopathies.  
In the 1980s research boosted up and concentrated at first on detecting a viral agent 
responsible for the disease, more than ever after a report by Mikol about the culture 
of an adenovirus from muscle biopsies of an IBM patient.5 Others, however, could not 
substantiate this finding nor could another possibly responsible persistent viral agent, 
in particular the mumps virus, be demonstrated. Moreover, an increasing number of 
case reports started to appear associating IBM with Sjögren disease, sarcoidosis, chron-
ic immune thrombocytopenia, lupus erythematosus, vitamin B12 deficiency, renal cell 
carcinoma and rheumatoid arthritis.6-12 Attention was also drawn to supposedly neu-
rogenic features in patients with IBM as the electromyogram showed fibrillation poten-
tials, decreased recruitment and frequent high amplitude and long duration motor unit 
action potentials along with grouped atrophic muscle fibers with an angular outline 
on transverse sections of muscle biopsies. Most importantly, Arahata and Engel com-
prehensively described the inflammatory features of IBM in a series of publications13-
17 while Lotz reported a large retrospective study comprising 48 patients in this time 
period.18 Furthermore, individual cases of failure of unusual and aggressive treatments 
such as total body irradiation and leucocytapheresis were published.19,20 Additionally, 
cases with severe dysphagia were described, many of whom had benefit from treat-
ment with cricopharyngeal myotomy.21-26
A new perspective was opened in 1991 when Mendell et al. observed small deposits of 
Congo red-positive material showing green birefringence on polarization microscopy in 
the vicinity of vacuoles and, rarely, perinuclearly or intranuclearly.27 Later, Askanas and 
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co-workers performed immunohistochemical studies showing the presence of deposits 
of amyloid b protein (Ab), Ab precursor protein and its mRNA, ubiquitin, a-1 antichymo-
trypsin, prion protein, apolipoprotein E, hyperphosphorylated tau, nicotinic acetylcho-
line receptor and fibroblast growth factor suggestive of an ongoing degenerative process 
similar to that in Alzheimer’s disease.28-36 The presence of many of these proteins in IBM 
muscle and of many other proteins that would follow has not been confirmed by other 
study groups. Nuclear breakdown was suspected in the formation of rimmed vacuoles 
when conspicuous amounts of a single-stranded DNA binding protein were found near 
nuclei and vacuoles.37 The relation between the mononuclear infiltrates and the degen-
erative findings remained enigmatic.
Treatment trials lasting up to six months were completed with intravenous immunoglob-
ulin with or without prednisone but failed to show unequivocal benefit.38-41
ePidemiology
At the time of the conception of the current study protocol (1996) IBM was not considered 
as rare as in the early years of its description, but it was still believed to be an underdiag-
nosed entity.42 Among all inflammatory myopathies it represented 16-28%.18,43 Popula-
tion-based figures were only available for the city of Göteborg, Sweden.44
clinical Picture
Since the recognition of IBM as a disease entity, the histopathology, pathogenesis, and 
therapy of the disease received more attention than its clinical features and clinical course. 
So far, none of the clinicopathological features had emerged as diagnostic or specific. 
Most clinical studies had been retrospective or, otherwise, small and possibly subject to 
selection bias. Consensus with regard to weakness distribution and progression of the 
disease and consequently a typical clinical picture that could help in diagnosing IBM on 
clinical grounds was lacking. So far, “typical” signs were based on review articles and 
some of these had not even been mentioned in the previously published larger patient 
series. The consequences of muscle weakness for the activities of daily life had been given 
only sparse attention.  
inflammation or degeneration
The inflammatory features of IBM consisted of predominantly focal mononuclear cellular 
infiltrates of mostly CD8-positive T-cells, with an endomysial location and a tendency to 
invade non-necrotic major histocompatibility complex (MHC) class I expressing muscle 
fibers. Invading T-cells showed restricted T-cell receptor gene usage.45,46 This suggested 
an antigen-driven autoimmune process. Although IBM had repeatedly been associated 
with autoimmune disorders, it remained unclear whether these were more frequent in 
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patients with the disease than in normal subjects. The results of immunomodulating 
treatment ranging from no to only a short lasting effect and the increasing discovery 
of degenerative histopathological features questioned the autoimmune hypothesis and 
ushered the question whether immunomodulating therapy could slow down the disease 
process. 
Many proteins normally present only at the post-synaptic part of the neuromuscular 
junction were reported to accumulate abnormally in IBM muscle fibers.47 Reports of ab-
normal single fiber electromyography created doubts on the function of the synapse.48,49
In short, inclusion body myositis was born as a histopathological entity. Epidemiological 
data were meager and the clinical features and the clinical course of the disease remained 
underexposed. In addition, doubt raised about its autoimmune origin, supported by the 
discovery of protein deposits associated with neurodegenerative processes and the lack 
of response to prednisone and other immunosuppressants. 
aims
The first aim of the present study was to survey the prevalence of IBM in the Neth-
erlands according to practical diagnostic criteria i.e. the presence of muscle weakness 
for at least six months and mononuclear endomysial infiltrates with invasion of mus-
cle fibers and rimmed vacuoles in the muscle biopsy. The second aim was to describe 
the clinical features and clinical course of the disease. The third aim was to investigate 
whether the major histocompatibility complex predisposed subjects to IBM and autoim-
mune disorders. Our fourth aim was to investigate the possible affliction of the neu-
romuscular junction in IBM. Finally, we studied whether the progression of IBM could 
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Epidemiological data on inclusion body myositis (IBM) are scarce, and possibly biased, 
because they are derived from larger neuromuscular centers. The present nationwide 
collaborative cross-sectional study, which culminated on July 1, 1999 resulted in identifi-
cation of 76 patients with IBM and the establishment of a prevalence of 4.9 patients with 
IBM per million inhabitants in the Netherlands. Several discrepancies suggest that this 
may be an underestimation. The most frequently identified pitfall in diagnosing IBM was 
an erroneous diagnosis of polymyositis or motor neuron disease.   
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introduction
Interest in inclusion body myositis has increased during the last two decades. Several se-
ries from large neuromuscular centers18,43,44,50,51 have been published and IBM is not now 
considered as rare as when first described; it represents 16% to 28% of all inflammatory 
myopathies.18,43,44 
IBM is thought to be the most common acquired progressive myopathy in those over age 
50 years, without reference to incidence or prevalence of the disorder for this age group.52 
Some authors have suggested that the condition is underdiagnosed.42 Population-based 
figures have only been published for the city of Göteborg, Sweden, with an incidence 
figure of 2.2 x 10-6/year.44 National figures have not been published. 
We have tried to establish the best approximation for the prevalence of IBM in the Neth-
erlands.
Patients & metHods
Organization and health care in the Netherlands
In the Netherlands, a patient with IBM will probably seek advice from a neurologist, in 
view of the slowly progressive and painless nature of the weakness experienced. If weak-
ness and elevated creatine kinase levels are presenting features, rheumatologic consul-
tation may be sought. Most neurologists are unfamiliar with the disease and thus seek 
advice from a neuromuscular center; all eight university hospitals have such a center.   
Case findings
All larger neurologic (n = 14) and rheumatologic (n = 11) centers in the Netherlands 
were approached by telephone and in writing in order to identify all patients diagnosed 
with IBM, chronic myositis, refractory myositis, or progressive myopathy of unknown 
origin with onset after age 45 years. Patients were identified through the national neu-
rologic and rheumatologic computerized coding systems, and the local databases of the 
Departments of Pathology. We drew additional attention to this project by publishing the 
aims of study, clinical features of the disorder, and diagnostic criteria in several Dutch 
medical journals. 
Inclusion criteria
The clinical notes from the patients recruited were screened for place of residence, gen-
der, date of birth, date of first out-patient visit, age at disease onset, prior diagnoses, date 
of diagnosis, distribution of weakness and course of the disease, and date and cause of 
death. The muscle biopsy specimens were reexamined. Patients fulfilling the European 
Neuromuscular Center (ENMC) criteria53 for definite (n = 72) or probable (n = 31) IBM 
were included (n = 103). 





We reviewed clinical data and biopsy specimens from 233 patients examined before 
July 1, 1999 in whom a diagnosis of IBM might have been considered; 103 patients ful-
filled the inclusion criteria. The first diagnosis was made in 1982 and since then a rising 
trend has persisted (figure). All but two patients were under neurologic care. Twenty-two 
patients died before July 1999. Five patients could not be traced. Accordingly, the total 
number of surviving patients on July 1, 1999 was 76. The number of inhabitants in the 
Netherlands at that time was 15,654,192, giving a prevalence of 4.9 x 10-6. When corrected 
for age and gender distribution, the prevalence was 16 x 10-6 for inhabitants over age 50 
years (22 x 10-6 for men, 10 x 10-6 for women). 
All patients were white. There were 50 men and 26 women resulting in a 2:1 ratio. This 
ratio did not change after correction for age and gender distribution in the general popu-
lation.
The mean time between first symptom and time of diagnosis was 8 years (range, 0.5 to 
29). The mean time which elapsed between symptom onset and first visit to a neurologist 
or rheumatologist (“patient delay”), and the time between the first visit and the diagnosis 
of IBM (“doctor’s delay”) were considerable (table 1). The mean age at onset for men and 
women was similar (table 1).
The prevalence of IBM varied considerably (from zero to 12 per million inhabitants) in the 
12 provinces of the Netherlands. 















































Figure.  Number of patients (Y-axis) with onset of symptoms (), time of first outpatient visit (n), 
and time of diagnosis (♦) per year seen between 1965 and 1999.
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first diagnoses were polymyositis (18%), motor neuron disease (17%), myopathy (13%) or 
polyneuropathy (9%). In only 16% of the patients was IBM the first diagnosis. 
Mean age at death of the deceased patients (n = 22) was 74 years for men (range, 56 to 
89; n = 13) and 77 years for women (range, 69 to 85; n = 9) compared with 72 years for 
men and 79 years for women in the general population. The cause of death was known 
for nine patients.  A direct relation between the neuromuscular disease and death was ap-
parent in two patients (one man): one patient with respiratory insufficiency and a second 
with chronic aspiration. 
Table 1 Age at onset, on July 1, and delay
Men, n = 50 Women, n = 26
Age on July 1, 1999 68 (48-84) 74 (52-85)
Age at onset, y 59 (40-75) 60 (39-77)
Patient’s delay, y 5.5 (0-26) 5.7 (0.5-19)
Doctor’s delay, y 1.5 (0-15) 3.5 (0-18)
Data are expressed as mean (range).
 






1. Presence of muscle weakness
2.  Weakness of forearm muscles, particularly finger 
flexors, or wrist flexors more than wrist extensors
3. Slowly progressive course 
4. Sporadic disease
5.  Mononuclear inflammatory infiltrates with invasion 
of non-necrotic muscle fibers
6. Rimmed vacuoles
7. Ultrastructure: tubulofilaments of 16 to 21 nm
1,2,3,4,5,6 or 1,3,4,5,6,7 (n = 72)† 
1,2,3,4,5 or 1,3,4,5,6 (n = 31)
* Comments on each of the items and items not relevant for the present purpose were omitted.
† According to other diagnostic criteria55,  16 patients would have definite IBM and 87 possible IBM.
discussion
As electron microscopy is not generally available in Dutch hospitals and the presence 
of amyloid deposition in light microscopy as a criterion for diagnosis of IBM was only 
recently suggested in 1995, it was not practical to apply the commonly used diagnostic 
criteria for IBM.55 We therefore used the ENMC-criteria,53 allowing a diagnosis of defi-
nite IBM on the basis of a combination of light microscopic and typical clinical features 
(table 2).
The exact prevalence of IBM has still not been established. Figures on its occurrence are 
highly relevant. First, epidemiologic data may be helpful in defining possible etiolog-
ic mechanisms. Second, these figures are indispensable for planning therapeutic trials, 
which are likely to be carried out for many years to come; up till now no therapeutic regi-
men has been shown to change the disease process consistently, nor has such an effect 
been excluded. 
The dense population and the small area of the Netherlands, together with well-orga-
nized administration and registration systems, determined the feasibility of gathering ep-
idemiologic data. These circumstances enabled us to undertake the largest study of IBM 
so far. In the case of IBM and other severe progressive disorders resembling IBM, such 
as motor neuron disease and polymyositis, it is common practice to refer these patients 
to a neurologist, a rheumatologist, or a neuromuscular center. One might expect that we 
would have seen a large proportion of the patients; our findings, however, suggest that 
substantial numbers of patients may have been missed. The constantly increasing num-
bers of patients with IBM diagnosed since 1982, together with the considerable doctor’s 
delay, suggest an underestimation due to ascertainment bias (figure). The substantial dif-
ferences in prevalence between the provinces also point in the same direction. If we as-
sume that the highest provincial prevalence represents the best approximation of the 
“real” prevalence, the national prevalence would rise from 4.9 x 10-6 to 12 x 10-6 and the 
total number of patients from 78 to 188. Finally, we were uncertain of a diagnosis of IBM 
in 21 (9%) of the 233 patients as they had the clinical features, but lacked one or more his-
topathological criteria in their muscle biopsy. This could be the result of sampling errors.
According to the incidence in Göteborg and a survival time of about 15 years, a preva-
lence of 33 x 10-6 is estimated.44 In Western Australia 15 patients from a population of 
1.8 million represent a prevalence of 8.2 x 10-6 (F. Mastaglia, personal communication). 
These figures differ from ours and, accordingly, geographically determined variations 
cannot be ruled out. 
Our patients’ age at onset was similar to that found in other studies.18,44,50,51 The delay 
in diagnosis was somewhat shorter in other studies (5.2 to 6.3 years) compared with the 
mean delay of 8 years in the present study. Although the male:female ratio has been 
reported to vary widely, from 1.3:1 to 6.5:1, on the basis of our results and those of other 
larger studies, a 2:1 ratio is probably correct. The differing ratios may reflect outliers from 
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The clinical features of inclusion body myositis (IBM) were of minor importance in the 
design of consensus diagnostic criteria, mainly because of controversial views on the 
specificity of signs and symptoms, although some authors reported “typical” signs. To 
re-assess the clinical spectrum of IBM, a single investigator using a standard protocol 
studied a cohort of 64 patients cross-sectionally. Symptom onset was before the age of 50 
years in 20% of cases. Only a few patients (14%) started with weakness other than that of 
quadriceps, finger flexor or pharyngeal muscles. The sequence of power loss was erratic, 
but onset of symptoms with quadriceps weakness predicted an earlier onset of dysphagia 
in older patients (> 56 years) compared with younger ones (< 56 years) (p = 0.02). De-
spite widespread weakness patients had favorable scores on three commonly used func-
tion scales and they kept their employment. Complete wheel-chair dependency was rare 
(3%). A dominant characteristic was the anatomical distribution of afflicted muscles: ven-
tral extremity muscle groups were more affected than dorsal muscle groups and girdle 
muscles were least affected, the latter preserving postural stability. Ankylosis, especially 
in extension of the fingers, was frequently present. Together with the sparing of intrinsic 
hand muscles it was helpful in the preservation of many skilful movements.
IBM has a unique distribution of muscle weakness. Ankylotic contractures are common. 
We feel that their joint impact on daily functioning is characteristic for the disease. 
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introduction
Inclusion body myositis (IBM) was recognized as a distinct myopathy in 1978.4 Since that 
time a vast amount of literature has been published concerning its histopathology, patho-
genesis, and therapy. The clinical features and the clinical course have received less at-
tention. So far nine papers described the clinical symptoms or signs in a minimum of 15 
and a maximum of 40 patients. Seven of these studies were retrospective and based on 
review of the medical records18,50,51,56-59 including one reporting the clinical findings in 18 
patients examined by one single investigator.44 Only two of the nine studies, describing 
up to 18 patients were cross-sectional in design.51,57
Weakness at the time of diagnosis was reported to be more severe in the lower than in the 
upper extremities50,51 and to be more or equally severe in proximal muscles compared to 
distal.44,50,57,58,60 If weakness was described for specific muscle groups, a different distri-
bution emerged: the knee extensors were considered more affected than the hip flexors 
and the wrist and finger flexors were more affected than the shoulder abductors.61 In the 
largest study so far the most severely affected muscle groups in cranio-caudal order were 
the biceps, triceps, iliopsoas, quadriceps and anterior tibial muscles.18 By contrast, later 
studies revealed the finger flexors to be most severely affected, along with the knee ex-
tensors and foot dorsiflexors.44,57,59,60 With regard to the least affected muscles each study 
showed a different pattern.57,59
The rate of progression, the mean decrease in muscle strength corrected for observed 
time, varied from 3.5%60 to 15.6% per year44 in retrospective studies and was found to be 
7.8% per year in a small prospective study.62 
“Typical” features are described in review articles without proper investigation. It is, there-
fore, worthwhile to conduct a reappraisal of both clinical features and clinical course in a 
large group of patients. A recognizable pattern of weakness may help in early diagnosis. 
Knowledge about functional limitations and rate of progression is clearly important to 
the individual patient, as well as for the design of future treatment trials. 
Hence, we addressed the following questions: 1) What were the presenting symptoms 
and age at onset and did these relate to the subsequent clinical course? 2) How was 
weakness distributed and was there a more or less typical pattern of affliction of muscle 
groups, and if so, what were the consequences in terms of function? 3) Were there neu-
rological signs other than weakness? 4) Was serum creatine kinase (sCK) activity related 
to the clinical course?
Patients & metHods
Patients
The recruitment procedure of the study cohort has been described previously.63 Between 
March 1996 and December 1999 we identified 95 Dutch IBM patients nationwide in whom 
a clinical picture of non-hereditary slowly progressive muscle weakness had existed for at 
least six months and who showed a histopathological picture of mononuclear infiltrates, 
predominantly within the endomysium and invasion of non-necrotic muscle fibers by 
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mononuclear cells, and basophilic vacuoles on hematoxylin and eosin staining or red-
rimmed vacuoles on Gomori trichrome staining. 
Medical records of these 95 patients were reviewed for sex, age at onset and disease dura-
tion for comparison of participating patients with non-participating patients. The Ethics 
Committee of the Leiden University Medical Center approved the study. 
Evaluation
One investigator (UB) examined all patients who consented to participate according to a 
standard protocol during a three-day clinical observation period comprising the follow-
ing elements.
i)  Renewed history-taking considering age, site of onset, dysphagia according to a stan-
dard questionnaire,64 progression, ambulation, and employment. Patients were as-
signed a functional grade according to the Barthel index,65 Rivermead mobility in-
dex66 and Brooke’s grading system67 
ii)  Physical examination, including manual muscle strength testing of 34 muscle groups 
comprising 3 neck-, 18 upper extremity- and 13 lower extremity muscle groups, was 
performed using the six-point British Medical Research Council (MRC) scale.68 The 
mean scores of each of 14 muscle groups tested three times with a hand-held myometer 
were added to a sum score, in Newtons.69 Facial muscles were graded as not, mildly or 
severely affected. Tendon reflexes were assessed for the biceps, triceps, knee extensors 
and foot flexors. Sensory modalities, scored as normal or abnormal, included vibration 
sense, position sense, sense for movement and direction, light touch and pinprick. 
iii)  Laboratory investigation of sCK activity.
The present study was retrospective with regard to part of the history-taking and cross-
sectional with regard to history-taking, physical- and laboratory examinations.
Statistical analysis
Dichotomous and ordinal variables were compared using Fisher’s exact test, continuous 
variables using the Mann-Whitney U test. The rate of weakness progression was ana-
lyzed by Cox’s proportional hazards forward stepwise regression model with sex and age 
at onset as covariates. Functional grading scales were analyzed by linear regression. 
Spearman’s rank correlation coefficient was applied to sCK activities and clinical para- 
meters. All statistical tests applied were two-tailed. P < 0.05 was considered significant. 
Unless otherwise stated, data are presented as mean ± standard deviation (range). 
results
Of the 95 identified IBM patients in the Netherlands, five were untraceable, nine died 
unexamined during recruitment and 17 refused. The remaining 64 patients, 43 men with 
a mean age of 67 ± 8 (47 to 85) and 21 women with a mean age of 73 ± 10 (51 to 84) were 
studied. Sixty-three patients were living at home, one in a nursing home. Based on the 
review of medical records the non-participating patients had a similar age, age at onset 
and sex distribution as the studied group.
InClusIon Body myosItIs: ClInICal features and ClInICal Course of the dIsease In 64 patIents
23
History
Onset Mean age at onset of weakness was 57 ± 9 (40 to 72) years for men and 59 ± 10 (39 to 
77) years for women. Thirteen patients (20%), 10 men, were younger than 50 years when 
symptoms began. The mean duration of symptoms was 10 ± 7 (1 to 32) years for men and 
14 ± 6 (4 to 29) years for women (p = 0.02). 
Weakness at onset Onset was most frequent in the quadriceps (63%) and less common 
in the finger flexors and pharyngeal muscles (Table). There was no statistically significant 
difference between the sexes, but onset with quadriceps weakness tended to occur more 
frequently in men.
Dysphagia Swallowing difficulties were the presenting symptom in six patients (9%). At 
history-taking 42 patients (66%) described one or more symptoms of dysphagia, i.e., a 
feeling of stasis and experiencing a need to swallow repeatedly, regurgitation or choking 
more than five times a month. 
Pattern and rate of progression Spreading of muscle weakness did not follow a specific 
directional pattern. The rate of spreading from one muscle group to another was studied 
between the quadriceps, finger flexors and pharyngeal muscles, as these were the most 
frequent first symptomatic muscle groups. In patients with onset in the quadriceps, onset 
at a higher age was associated with earlier spreading to pharyngeal muscles (Cox’s pro-
portional hazards, p = 0.02) and showed a similar, but non-significant, trend to earlier 
finger flexor weakness (Figure 1). The small groups with onset in the finger flexors and 
pharyngeal muscles did not show a similar association. For individual patients, however, 
the experienced rate of progression varied considerably between specific muscle groups 
as exemplified by two illustrative cases. Case 1: at the age of 52 years, a woman noticed that 
heavy objects slipped from her fingers. One year later she required aid from her arms when 
climbing stairs. In her seventies, food started to get stuck in her throat. At the age of 81 she 
was still able to walk without aid and was totally independent with regard to normal daily 
activities, but she needed a percutaneous endoscopic gastrostomy for nutrition. Case 2: at 
Table Sex-specific frequency of the first symptomatic muscle group 
All patients Male Female p pc
n % n % n %
Quadriceps 40 63 31 72 9 43 0.03 0.09 (ns)
Finger flexors 9 14 5 12 4 19 0.46 1.00 (ns)
Pharynx 6 9 2 5 4 19 0.08 0.24 (ns)
Other 9 14 5 12 4 19
Total 64 100 43 21




Figure 1A and 1B  Kaplan-Meier curves with groups divided on the basis of median age at onset 
(---- <56 years, — ≥ 56 years). With higher age at onset, a faster progression 
to dysphagia is shown in patients with quadriceps weakness as initial symp-
tom (A), and a similar trend to finger flexor weakness (B) 
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the age of 50 years a man found he let a heavy bag of rubbish slip from his fingers. Subse-
quently, when aged 54, he had problems biking uphill. At the age of 58 years he became 
wheelchair-bound and almost completely paralyzed and died aged 63 due to recurrent 
aspiration.
Ambulation Patients remained ambulant for many years. Forty-seven cases (73%) had 
experienced periods of frequent falls, described as sudden falls on the knees or as trip-
ping. The number of falls decreased after a variable period of time but increased again as 
weakness progressed. In eight patients falls resulted in bone fractures. 
Forty-seven patients (73%) used an assistive device for mobility. Nine patients (14%) used 
a wheelchair; this included two totally wheelchair-dependent patients and seven who 
were still able to walk with support. Mean time between symptom onset and wheelchair 
use was 13 ± 8 (6 to 32) years. Frequent falls or fear of falling, not the inability to walk, was 
the initial reason for wheelchair use in all cases. 
Miscellaneous Dry eyes as a result of facial weakness occurred in three women and drool-
ing in one other. Myalgia was not a feature of IBM: three patients suffered diffuse pain, in 
two of whom it had occurred after discontinuation of corticosteroids. Only two patients 
had muscle cramps restricted to gastrocnemius muscles during the night. 
Functional grading and employment The cross-sectional median scores on the Barthel 
index (0-20 points scale), Brooke’s grading system (3-22 points scale) and Rivermead mo-
bility index (0-15 points scale) were 19 (range 6 to 20), 5 (3 to 16) and 13 (0 to 15) for men 
and 17.5 (7 to 20), 7.5 (4 to 14) and 10.5 (0 to 14) for women, respectively (with 20, 3 and 15 
points as the respective best function scores). Thus men scored significantly better than 
women (p < 0.002 for each of the 3 scales). This difference, however, was associated with 
the longer symptom duration in females (see above) and not with sex itself, age, or age 
at onset.
None of the 64 patients had stopped working before retirement (in the Netherlands be-
tween the ages of 60 and 65) because of weakness. Simple adaptations, e.g. height adjust-
able chairs, were sufficient to maintain employment. 
Treatment A majority of 41 patients had never received immunosuppressive therapy. In 
19 patients treatment had been short lasting because of lack of benefit or adverse events. 
At examination four patients were receiving immunomodulating therapies. 
Cross-sectional examination
Muscle weakness Viewed from the anatomical position a rough recurring pattern of ex-
tremity muscle weakness was observed. Muscles located ventrally were the most fre-
quently and severely affected (Figure 2). Dorsally located muscles were also frequently 
affected but clearly less severely as MRC scores ≤ 3 were rare. Girdle muscles and distal 
muscles of the hands with a spreading or adducting function were those most spared in 
frequency and severity. This pattern was similar for both sexes.
Despite severe weakness and atrophy of the biceps, elbow flexion was often retained due 
to obvious sparing of the brachioradialis muscle. Although the superficial flexors of the 
fingers and flexors of the wrist were generally more affected than the respective extensors 
on the same side, this was not the case in 16% of these muscles. The deep finger flexors 
were always more severely affected than the superficial finger flexors. Weakness often 
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Figure 2  Severity of muscle weakness according to MRC scores (5 in black, 4 in grey and ≤ 3 in 
white) and frequency of affliction of muscle groups for the total group of patients at cross-
sectional examination. Percentages are based on the total number of muscle groups on 
both sides. Muscle groups are ordered from most (left) to least frequent (right) affliction
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differed among fingers. Even slight weakness of the deep finger flexors always resulted 
in inability to completely cover the fingernails of digits II - V when making a fist. The 
interosseus muscles were generally spared and atrophy was never conspicuous, taking 
the advanced age of most patients into account. Lumbrical sparing resulted in a remark-
able resting position if accompanied by severe finger flexor weakness: almost straight 
fingers at the proximal-  and distal interphalangeal joints with about 80° flexion at the 
metacarpophalangeal joint. The adductor pollicis was weak in only 4 patients (6%) and 
the opponens pollicis in 9 (14%), neither ever scoring less than MRC grade 4, whereas 
other thumb muscles were commonly affected. This peculiar sparing pattern of thumb 
muscles, even in the very disabled, allowed patients to maintain some form of grip such 
as on a spoon or a ballpoint. 
As a rule, in right-handed patients the right arm was stronger than the left arm.
A waddling gait was seen in five patients (8%) only. Hip abductor weakness was usu-
ally symmetric and slight, never less than MRC grade 4, although present in 26 patients 
(41%). In the legs atrophy was most obvious in the quadriceps, especially the vastus me-
dialis muscle. 
Twenty-six patients (41%) had mild symmetric facial muscle weakness, the orbicularis oc-
uli being the most frequently and severely affected muscle. Six patients (9%), all women, 
had severe facial muscle weakness with inability to close the eyes. Extra-ocular muscles 
were never affected and ptosis was not seen. Nor were fasciculations observed.
Impaired passive joint movement (ankylosis or contracture) Most apparent was im-
paired passive flexion of interphalangeal joints, observed in 25% of patients with finger 
flexor weakness. The stretched fingers along with the spared function of the interos-
seus and lumbrical muscles enabled patients to typewrite or to pick up a mug with 
two straight fingers through and the adducted thumb upon the ear. Impaired passive 
dorsiflexion of the foot was observed in 10 (16%) patients, including three females who 
were no longer able to stand or walk without high heels. Passive shoulder movements 
were limited in four patients only. Three wheelchair-dependent patients had impaired 
passive extension of the elbow. Forty-three (67%) patients experienced pain with pas-
sive flexion of the knee beyond 90°. Impaired passive extension of the knees was not 
observed. 
Tendon reflexes The knee tendon reflex could be vivid in the presence of severe quadri-
ceps atrophy. Tendon reflexes were absent on at least one side at the biceps in 23 patients 
(36%), the triceps in 26 (41%), the knee in 23 (36%) and the Achilles in 39 patients (61%). 
There was no significant left-right asymmetry for the group. 
Sensory signs Abnormalities were slight, restricted to the lower limbs and present in no 
more than ten patients (16%) except for an absent vibration sense at the ankles in 34 (53%) 
patients. Pinprick and position sense were normal in all patients. 
Cross-sectional sCK-activity.
Median sCK activity at the time of cross-sectional examination was 501 U/l (64  to 3360) for 
men and 246 (44 to 802) for women (normal values: <200 U/l and <170 U/l, respectively), 
the sCK activity being elevated in 35 men (79%) and 15 women (75%). Serum CK activity 
was not related to muscle strength sum scores, age, age at onset or symptom duration. 
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Four patients (6%), all men with a symptom duration of less than 12 years who were 
otherwise not different from other patients, had activities higher than 12 times the upper 
limit of normal. 
discussion
The patients described in this cross-sectional study can be considered a representative 
sample of all known IBM patients in the Netherlands. As there is no golden standard 
for the diagnosis of IBM we used criteria, which were both practical in clinical use and 
fulfilled at least to the consensus criteria of “probable IBM” according to the European 
Neuromuscular Centre.53 The present series concerns the largest group of IBM patients 
studied so far by a single investigator using a standard protocol.      
It has been suggested that IBM generally develops after the age of fifty.56  In our study it 
is noteworthy that in a considerable group of patients, one-fifth, the onset of symptoms 
was between 39 and 50 years. This is in accordance with the findings of at least three 
other large studies reporting frequencies of 17%, 18% and 19% of patients below the age 
of 50.18,44,51 Although the site of weakness at onset varied, the vast majority of our patients 
(86%) commenced with weakness of the quadriceps, finger flexors or pharyngeal mus-
cles. The only other study that investigated the first symptomatic muscle groups reported 
similar initial symptoms.60 
An earlier age of onset was significantly associated with a lower rate of weakness pro-
gression from the quadriceps to the pharyngeal muscles and likewise to finger flexors. 
Accordingly, none of our patients had to discontinue their occupation, implying limited 
severity of disease before retirement. This is in contrast to the common conception in 
neuromuscular disorders that tend to be more disabling with earlier onset such as in 
dystrophinopathies and spinal muscular atrophy. A previous study also suggested faster 
progression to disability in patients with onset beyond 60 years of age.70 As age of onset is 
an independent predictor of progression this result needs to be taken into account in the 
design of future treatment trials. 
The rate of progression of weakness varied considerably between specific muscle groups 
within a single patient and between patients as illustrated by the two case descriptions. 
The wide range in time (6 to 32 years) between symptom onset and wheelchair depen-
dency in our patients also underscored differences in rate of progression. Time to non-
ambulatory status in other studies ranged between 4 and 9 years44 and between 6 and 
14 years.60 The extent of fear of falling in various individuals may have influenced these 
figures as not the inability to walk, but the fear of falling or frequent falls were the promi-
nent reasons for wheelchair use. Although falls were common initially, mainly as a result 
of knee- and foot extensor weakness, the vast majority of these patients were ambulant, 
probably because they were able to adapt their walking pattern to their weakness. The 
scores on function scales, although not specifically designed for IBM, and the fact that 
almost all patients were living at home underlined the functional independence of IBM 
patients. 
Myalgia was not a symptom of IBM. Although myalgia was never a presenting symptom 
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in previous studies,18 it was observed during the course of the disease in 20% to 42% of 
patients.18,50,51 It is unclear to what extent myalgia resulted from discontinuation of cor-
ticosteroids. 
The distribution of muscle weakness for the patient group as a whole showed that none 
of the measured muscles, including the facial muscles, was entirely spared with the ex-
ception of external eye muscles. Facial weakness was common in our patients, but only 
severe in females. Other studies reported facial weakness in 4% to 53% of patients,58,60,61 
while others reported this to be rare.18,50 
Taking the patient group as a whole, the distribution of muscle weakness showed a pat-
tern that differed from that of other neuromuscular disorders. The most frequently and 
severely afflicted muscles were all located ventrally and were flexors in the arms and ex-
tensors in the legs, whereas the most spared muscles were located at the girdles and distal 
parts of the extremities and were serving mainly adducting and abducting movements. 
The sparing of these specific muscle groups could be related to the long maintenance 
of ambulation and independence in daily functioning: i) the relative sparing of the hip 
abductors and hip adductors provided the stability required to walk, even with virtually 
absent quadriceps function; ii) the spared shoulder muscles assisted the patient in rising 
from a chair as adducted and externally rotated upper arms were used to push the body 
up; iii) important finger movements such as adduction and opposition of the thumb re-
mained possible because of sparing of selective thumb muscles and lumbricals. 
Contractures have not been previously reported but were seen in a considerable propor-
tion of our patients. Of particular interest is the contracture of the fingers along with the 
spared lumbricals that enabled patients to keep using their fingers for skilful movements, 
thus supporting independence.
We could not confirm the suggestion of others that presence or absence of the knee ten-
don reflex was related to the muscle mass.18,50 Reflexes do not, therefore, help to distin-
guish IBM from motor neuron disease.
About 94% of patients had a sCK value lower than 12 times the upper limit of normal. 
However, as some patients, especially men in the early course of the disease, had higher 
sCK activities, this limit does not exclude IBM as was proposed in American diagnostic 
criteria for “possible IBM”.55 In previous large studies sCK maximum values varied be-
tween 5 and 15 times the upper limit of normal.18,44,50,58-60
In conclusion, as far as the clinical features and clinical course of IBM are characteristic, 
the features can be summarized as follows: time of onset of symptoms is generally after 
the age of 40; onset of symptoms shows preference for the quadriceps, especially in 
men, and for finger flexors and pharyngeal muscles, in this order of frequency; weak-
ness is progressive, the rate of progression is highly variable, both intra- and inter-in-
dividually; spreading of weakness is erratic; older age of onset is associated with faster 
weakness progression; ventrally located muscles are the most affected whereas girdle 
muscles are comparatively spared and support ambulation and independence; facial 
weakness is common; impaired passive joint movements are a feature of IBM, but can 
both impair and support independence; sensory signs are inconspicuous; sCK activity 





Muscle weakness in inclusion body myositis
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Whether or not the neuromuscular junction (NMJ) is affected in inclusion body myositis 
(IBM) is unclear. To evaluate NMJ function, repetitive nerve stimulation (RNS) with fre-
quencies of 1, 3, 5 and 10 Hz was applied to the ulnar nerve in 42 patients with IBM. 
None of the patients showed an abnormal decrement. Our study provides no evidence 
for a NMJ disorder in IBM. Abnormal results on low-rate RNS in patients with muscle 
weakness most probably exclude IBM. 
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introduction
Inclusion body myositis (IBM) is a slowly progressive myopathy with an insidious onset 
after the age of 40 years with a male preponderance. Initial symptoms often relate to 
weakness of the quadriceps muscles, distal arm muscle or pharyngeal muscles.71 The 
etiology of IBM is unknown. Endomysial inflammatory infiltrates, invaded muscle fibers, 
rimmed vacuoles, and abnormal accumulations of a host of proteins such as amyloid β 
(precursor) protein, nicotinic acetylcholine receptor and its RNA, rapsyn, α1-antichymo-
trypsin, apolipoprotein E and cellular prion protein in muscle fibers are prominent his-
topathological features of the disease.47 Most of these accumulated proteins are normally 
only present at the post-synaptic part of the neuromuscular junction. Mild to moderate 
increases of jitter and blocking have been reported in IBM patients48,49,72 using single 
fiber electromyographic (SFEMG) studies. A reduction of acetylcholine receptors at the 
neuromuscular junctions of patients with myositis has been reported, as in myasthenia 
gravis.73 Together this suggests a possible NMJ dysfunction in IBM. Jitter by itself does 
not cause muscle weakness, but impulse blocking does. In repetitive nerve stimulation 
abnormality is due to blocking. As far as we know, we for the first time report the use 




IBM patients were recruited from a series of 86 patients known to be living in the Nether-
lands. The recruitment procedure has been reported in detail.63 Out of these 86 patients, 
5 patients could not be located, 6 had died prior to assessment and 14 refused participa-
tion. Logistical reasons further restricted inclusion to 42 patients, 37 of whom had definite 
and five probable IBM according to clinical and histopathological criteria.53,63 All patients 
gave informed consent. To compare the selection of participating patients with the popu-
lation cohort, the medical records of all 86 patients were reviewed for age (at onset), sex 
and disease duration. The local ethics board had approved the study.
Methods
All 42 patients were prospectively tested. One investigator (UB) assessed muscle strength 
according to the Medical Research Council (MRC) six-point scale.68 Before RNS testing, 
skin temperature was raised to at least 32 °C with hot water baths. RNS of the ulnar nerve 
was performed with self-adhesive recording electrodes of 28 x 22 mm (Nicolet Instru-
ments, Madison, Wisconsin) over the hypothenar muscles of the right-sided hand. The 
ulnar nerve was stimulated just proximal to the wrist at 1.5 times the lowest intensity 
resulting in a supramaximal response. The hand and stimulator were immobilized with 
tape.
RNS was performed in trains of 10 stimuli at 1, 3, 5 and 10 Hz. Skin temperature, stimula-
tion intensity and frequency as well as the amplitude and area of all compound muscle 
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action potentials (CMAPs) was noted. To study the decrement the amplitude of the small-
est CMAP during a train of stimuli was expressed as a percentage of the first CMAP am-
plitude of that train. Test methods and the abnormality criterion of a decrement in am-
plitude equal to, or more than, 10% have been described previously.74 The initial CMAP 
amplitude had to be sufficiently high for reliable analysis, i.e., preferably ≥ 0.5 mV. 
results
The median age of the 42 IBM patients, 31 men, was 69 years (range 50-83). The median 
disease duration was 11 years (range 1-29). The male sex was over-represented in the 
investigated group compared with the population group of 86 patients that had a male 
to female ratio of 2:1. 
At the time of investigation 18 patients (43%) had apparent weakness of the hypothenar 
muscles of MRC grade 4 or less. Mean initial CMAP amplitude was 5.4 ± 1.9 (range 2.5-9.9) 
mV and the mean initial CMAP area (both negative phase) was 13.7 ± 5.7 (range 4.8-26.6) 
mVms. No patient had an abnormal CMAP amplitude decrement at any frequency stimu-
lation, nor was there any trend towards a decrease in mean amplitude (table). 





 1 Hz 99 ± 3 (91-107)   98 ± 3  (90-103)
 3 Hz 99 ± 3 (91-106)   98 ± 2  (91-103)
 5 Hz 100 ± 4 (94-112)   98 ± 3  (90-103)
10 Hz 105 ± 5 (95-117) 102 ± 4 (93-114)
CMAP, compound muscle action potential.
Values for minimum amplitude or area indicate the lowest response amplitude or area in a train of responses 
to 10 stimuli, expressed as percentage of the first response. Data are presented as mean ± standard deviation 
(range).
discussion
Previous reports suggested a neuromuscular transmission disorder in IBM using SFEMG. 
One study reported an increased mean jitter of 83 µsec compared with an abnormality 
threshold of 60 µsec in 7 of 7 IBM patients.48 Another study reported less abnormal jitter 
(mean = 46.5 µsec, normal <40.5 µsec) in 7 of 12 IBM patients49 and a third study report-
ed increased jitter or blocking in 5 of 17 patients, but only in 1 of 17 at multiple sites.72 We 
performed RNS in a large group of IBM patients, but RNS never showed abnormalities, 
even though the muscles examined were clinically affected. Although the sensitivity of 
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RNS for neuromuscular transmission disorders is lower compared with SFEMG but its 
specificity higher, it would seem that neuromuscular transmission in IBM was not essen-
tially affected and synaptic dysfunction did not contribute to weakness in IBM. There-
fore, we now believe that the SFEMG abnormalities in IBM are insignificant, as they are 
in other chronic myopathies.  
Interestingly, our results may be of help in discriminating IBM from the Lambert-Eaton 
myasthenic syndrome (LEMS) and motor neuron disease (MND). Due to similarities in 
distribution of age, sex and muscle weakness at presentation clinical distinction between 
these disorders can be difficult. A decremental response with low frequency RNS is in-
variably present in LEMS. In IBM and MND conventional needle electromyography find-
ings are not distinctive as IBM patients may also show spontaneous muscle fiber activity, 
polyphasic motor unit action potentials (MUAP) and appear to have an increased num-
ber of long duration and high amplitude MUAP’s as in MND. However, as up to 53% of 
patients have a decremental response in MND75-77 the presence of an abnormal low-fre-
quency RNS is most probably distinctive between MND and IBM.
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Whether autoimmune mechanisms play a role in the pathogenesis of inclusion body my-
ositis (IBM) is unknown. Human leucocyte antigen (HLA) analysis in 52 patients, includ-
ing 17 with autoimmune disorders (AIDs), showed that patients were more likely to have 
antigens from the autoimmune-prone HLA-B8-DR3 ancestral haplotype than healthy 
control subjects, irrespective of the presence of AIDs. Patients lacked the apparently pro-
tective HLA-DR53 antigen. The results provide further support for an autoimmune basis 
in IBM.  
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introduction
Inclusion body myositis (IBM) is a slowly progressive inflammatory myopathy with a 
male predominance and preferential weakness onset in the quadriceps muscles, fin-
ger flexors or pharyngeal muscles. In general, immunosuppressive treatment has no 
beneficial effect.78 Whether autoimmune mechanisms play a role in the pathogenesis 
has not yet been established.
IBM is histologically characterized by signs of an ongoing degenerative process and 
inflammation with invasion of major histocompatibility complex (MHC) I-expressing 
muscle fibers by CD8+ T-cells with a restricted T-cell receptor gene usage. The MHC 
region on chromosome 6 has a key function in the presentation of short pathogen-
derived peptides to T-cells. Genetic susceptibility for many autoimmune disorders 
(AIDs) has been linked with the MHC. To determine whether the MHC predisposes 
subjects to IBM and other AIDs we investigated 1) the frequency of AIDs in IBM, 
2) human leucocyte antigen (HLA) class I and II antigen associations in Dutch pa-
tients, and 3) relations between associated HLA antigens and clinical features. 
Patients & metHods
Between March 1996 and September 1999, 86 IBM patients were known to be living in 
the Netherlands. The recruitment process of these patients has been reported.63 Five 
patients could not be located, 6 died prior to assessment, 12 refused participation and 
11 could not be included for logistical reasons. The remaining 52 patients, 47 with 
definite and 5 with probable IBM,63 all Caucasian, were included. All patients gave 
informed consent. The local ethics board approved the study. 
Patients and spouses (if available) were questioned by one investigator, paying par-
ticular attention to age and symptoms at onset and presence of AIDs. Reports of AIDs 
were verified by information from the treating physicians. 
Typing of HLA class I and II antigens was performed by a complement-dependent 
lymphocytotoxicity technique using locally prepared sets of anti-HLA allosera and 
monoclonal antibodies. A panel of randomly selected, serologically typed, healthy 
Dutch blood donors (N = 2,440) served as a control population.79 A few patients were 
also typed using DNA-based methods.
The antigen frequencies of patients and controls were compared using the χ2 test. 
Odds ratios were calculated using the Woolf-Haldane method. Relations between 
HLA antigens and age at onset were investigated by forward multiple linear regres-
sion analysis. Antigens linked with IBM were related to gender, site of onset, and 
presence of AIDs using the χ2 test or Fisher exact test as appropriate and corrected 




Table Frequencies of HLA class I and II antigens in IBM patients and controls
HLA antigen IBM, n (%) Controls, n (%) OR 95% CI p value pc value
A1 25 (48)  747 (31)  2.1 1.2-3.6 0.01 0.44  
A3 24 (46)  700 (29)  2.1 1.2-3.7 0.008 0.40  
A9 12 (23)  472 (19)  1.3 0.7-2.4 0.48 1.00
A10  3 (6)  170 (7)  0.9 0.3-2.8 1.00 1.00
A11  4 (8)  281 (12)  0.7 0.3-1.9 0.51 1.00
A28  3 (6)  244 (10)  0.6 0.2-1.9 0.48 1.00
A29  0 (0)  119 (5)  0.2 0.0-3.0 0.18 1.00
A30  0 (0)   85 (3)  0.3 0.0-4.3 0.26 1.00
A31  1 (2)  146 (6)  0.5 0.1-2.3 0.37 1.00
A32  4 (8)  149 (6)  1.4 0.5-3.8 0.56 1.00
A36  1 (2)   10 (0)  7.2 1.3-40.9 0.20 1.00
B5  8 (15)  289 (12)  1.4 0.7-3.0 0.39 1.00
B7 13 (25)  668 (27)  0.9 0.5-1.7 0.88 1.00
B8 36 (69)  554 (23)  7.5 4.2-13.6 <10-5 <10-5 *
B12  5 (10)  617 (25)  0.3 0.1-0.8 0.009 0.41
B13  0 (0)  109 (4)  0.2 0.0-3.3 0.17 1.00
B14  1 (2)   70 (3)  1.0 0.2-5.0 1.00 1.00
B15  7 (13)  386 (16)  0.9 0.4-2.0 0.85 1.00
B16  3 (6)  175 (7)  0.9 0.3-2.7 1.00 1.00
B17  0 (0)  162 (7)  0.1 0.0-2.1 0.05 0.95 
B18  2 (4)  158 (6)  0.7 0.2-2.6 0.77 1.00
B21  3 (6)   54 (2)  3.1 1.0-9.5 0.11 1.0
B22  1 (2)  142 (6)  0.5 0.1-2.4 0.36 1.00
B27  3 (6)  157 (6)  1.0 0.3-3.1 1.00 1.00
B35 12 (23)  429 (18)  1.4 0.8-2.7 0.36 1.00
B37  0 (0)   99 (4)  0.2 0.0-3.7 0.27 1.00
B40  3 (6)  435 (18)  0.3 0.1-1.0 0.03 0.79 
B70  1 (2)   30 (1)  2.2 0.4-11.3 0.51 1.00
DR1 18 (35)  473 (20)  2.2 1.2-3.9 0.01 0.55 
DR3 41 (79)  599 (25) 10.8 5.6-20.9 <10-5 <10-5 *
DR4  3 (6)  679 (28)  0.2 0.1-0.5 <10-4 0.007 *
DR7  2 (4)  459 (19)  0.2 0.1-0.7 0.003 0.19 
DR8  0 (0)  128 (5)  0.2 0.0-2.7 0.11 0.1
DR9  1 (2)   58 (2)  1.2 0.2-6.0 1.00 1.00
DR10  0 (0)  100 (4)  0.2 0.0-3.6 0.27 1.00
DR11  5 (10)  340 (14)  0.7 0.3-1.7 0.42 1.00
DR12  0 (0)  108 (5)  0.2 0.0-3.2 0.17 1.00
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results
The mean age of the 52 examined patients was 67 ± 8 years for men (n = 36) and 71 ± 10 
for women (n = 16) with a mean age at symptom onset of 58 ± 8 years for men and 56 ± 
9 years for women. Mean duration of symptoms was 9 ± 5 years for men and 15 ± 7 years 
for women. The studied patient group was representative for the Dutch IBM population 
cohort with respect to age and sex distribution.
Seventeen patients (33%) had AIDs, including three patients with multiple disorders. 
These were autoimmune thyroid disease (n = 6), rheumatoid arthritis (n = 4), type I dia-
betes mellitus (n = 2), Sjögren disease (n = 2), psoriasis (n = 2), vitiligo, sarcoidosis, celiac 
disease, and ulcerative colitis (all n = 1). 
HLA class I B8 and class II antigens DR3, DR52 and DQ2 were more likely to be found in 
patients with IBM than in control subjects (table). The B8-DR3-DR52-DQ2 haplotype was 
found in 35 patients (67%). In the remaining 17 patients, the distribution was as follows: 
Six (12%) had DR3-DR52-DQ2, one patient had B8-DR52, five patients (10%) had DR52, 
whereas in five patients, none of the antigens were found. Of the five “probable IBM” pa-
tients three had the complete haplotype associated with the disorder, one had part, and 
one none of the associated antigens. The B8-DR3-DR52-DQ2 haplotype was present in 11 
of 17 patients (65%) with AIDs and in 24 of 35 patients (69%) without AIDs.
As HLA-A1 is known to be in positive linkage disequilibrium with the above-mentioned 
haplotype, its frequency was the subject of further study. In the group with the B8-DR3-
DR52-DQ2 haplotype, 22 of 35 patients were HLA-A1 positive and 13 of 35 were A1 nega-
HLA antigen IBM, n (%) Controls, n (%) OR 95% CI p value pc value
DR13 17 (33)  669 (28)  1.2 0.7-2.2 0.53 1.00
DR14  0 (0)  127 (5)  0.2 0.0-2.7 0.11 1.0
DR15 10 (19)  414 (26)  0.7 0.4-1.4 0.34 1.00
DR16  4 (8)   43 (2)  4.9 1.8-13.4 0.02 0.67 
DR52 47 (90) 1641 (67)  4.2 1.7-10.2 0.0002 0.01 *
DR53  4 (8) 1088 (45)  0.1 0.0-0.3 <10-5 <10-5 *
DQ2 41 (79)  881 (37)  6.1 3.1-11.7 <10-5 <10-5 *
DQ4  0 (0)   29 (3)  0.3 0.0-4.7 0.40 1.00
DQ5 22 (42)  300 (35)  1.4 0.8-2.4 0.3 1.00
DQ6 26 (51)  453 (50)  1.0 0.6-1.8 1.00 1.00
DQ7  9 (18)  652 (28)  0.6 0.3-1.2 0.12 1.0
DQ8  0 (0)  184 (20)  0.0 0.0-0.6 <10-5 0.001 *
DQ9  2 (4)  71 (8)  0.6 0.2-2.2 0.42 1.00
* frequency difference significant, pc < 0.05
HLA = human leucocyte antigen; IBM = inclusion body myositis; pc = p value corrected for 61 split and 61 
broad informative comparisons.
Table Frequencies of HLA class I and II antigens in IBM patients and controls (continued)
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tive, whereas in the group of 17 with the incomplete associated haplotype, 3 patients had 
A1 (p = 0.003 for frequency difference). None of the other linked antigens were found in 
these three patients.
The presence of HLA-DR4, HLA-DR53 and HLA-DQ8 in patients was significantly less 
frequent than in control subjects.
As the results indicated a preference for the A1-B8-DR3-DR52-DQ2 haplotype, we inves-
tigated the possibility of associations between these HLA antigens and clinical features. 
Presence of HLA-A1 was associated with an earlier onset (p = 0.017, adjusted R2 = 0.09, 
B = −5.4, 95% CI for B = −9.8 to −1.0). The mean age at onset in HLA-A1-positive patients 
was 54.3 ± 8.4 years and in A1-negative patients 59.7 ± 7.5 years. The individual associ-
ated antigens did not relate to gender, a preferential site of onset (i.e., pharyngeal, quad-
riceps, or finger flexor weakness or other type of weakness), or presence of AIDs. 
The HLA-DR53 antigen was present in only four patients, none of whom showed overt 
clinical differences compared with HLA-DR53-negative patients.  
discussion 
In this study of a large cohort of IBM patients, we found an increased frequency of HLA-
B8 and HLA-DR3 antigens in patients compared with control subjects. The B8-DR3 hap-
lotype has been associated with AIDs such as myasthenia gravis, Lambert-Eaton myas-
thenic syndrome (LEMS), type I diabetes mellitus, sarcoidosis, celiac disease and Graves 
disease. Our results confirm previously described associations of IBM with HLA-B8 and 
HLA-DR3 in Australians80 and with HLA-DR3 and HLA-DR52 in Americans.81 Our find-
ings are also in accordance with an American DNA-based study.82 In our patients, the B8-
DR3 haplotype also included HLA-DR52 and HLA-DQ2 and indirectly HLA-A1, which 
are known to be in linkage disequilibrium. 
HLA-A1was associated with an earlier onset. Similarly, HLA-B8 has been related to earlier 
disease onset in LEMS and myasthenia gravis.18,83 The concept that this autoimmune-
prone haplotype is implicated in the development of IBM is certainly quite feasible. In-
terestingly, the MHC did not provide any indication why there is a male predominance 
in IBM.
Our patients had a high frequency of AIDs but their presence did not influence the fre-
quency of the B8-DR3-DR52-DQ2 haplotype in the IBM cohort. We found no preference 
for target-specific AIDs or for AIDs with a suspected T-cell-mediated pathogenesis. Com-
pared with Dutch patients with LEMS, an antibody-mediated AID studied using compa-
rable methods, patients with IBM had a similar frequency of additional AIDs.83 The fact 
that we paid particular attention to AIDs may have resulted in a higher frequency than 
the 3 to 15% reported in retrospective studies.18,50,84 
It is obvious that the increased frequency of the HLA-B8-DR3 haplotype did not lead to 
a proportional lowering of other common haplotypes such as those of HLA-DR1 and 
HLA-DR2 antigens.
HLA-DR53 was uncommon in IBM as were HLA-DR4, HLA-DQ8 and to a lesser extent 
HLA-DR7. As HLA-DR53 was the shared denominator in the common haplotypes of 
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these antigens, the negative association could be attributed to a low frequency of DR53. 
Hence, the increased risk for IBM could also be ascribed to an absence of HLA-DR53. 
The high frequency of AIDs, the very strong association with the extended HLA-DR3 
haplotype linked to many of these AIDs, the protective effect of HLA-DR53, the influence 
of HLA-A1 on the age at onset and the similarities between regionally different Caucasian 
populations all point to an important immunogenetic role of the MHC in the predisposi-
tion for developing IBM. These findings also support the inflammatory histopathologic 
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We investigated whether 5 to 20 mg per week oral methotrexate (MTX) could slow down 
disease progression in 44 patients with inclusion body myositis in a randomized dou-
ble-blind placebo-controlled study over 48 weeks. Mean change of quantitative muscle 
strength testing (QMT) sum scores was the primary study outcome measure. QMT sum 
scores declined in both treatment groups, −0.2% for MTX and −3.4% for placebo (95% 
confidence interval =  −2.5% to +9.1% for difference). There were also no differences in 
manual muscle testing (MMT) sum scores, activity scale scores and patients' own assess-
ments after 48 weeks of treatment. Serum creatine kinase (CK) activity decreased signifi-
cantly in the MTX group. We conclude that oral MTX did not slow down progression of 
muscle weakness but decreased serum CK activity.
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introduction
Inclusion body myositis (IBM) is a progressive muscle disorder with unknown etiol-
ogy. Muscle biopsy specimens show inflammation and depositions of proteins similar 
to those seen in degenerative disorders,35,85,86 processes that do not seem to be closely 
related as they do not co-localize.87
Immunosuppressive therapies have yielded no or only short lasting improvement of 
muscle strength.39,41,40,88,89 Whether immunosuppressive treatment can slow down 
disease progression has not been studied. 
Oral methotrexate (MTX) is a widely used, effective and well-tolerated treatment in 
rheumatoid arthritis.89-90 The weekly regimen facilitates compliance and MTX has 
low cost. In the present study, we compared the efficacy and tolerability of MTX and 
placebo in slowing down disease progression in IBM.
Patients & metHods
From April 1996 until December 2000, we conducted a nationwide, randomized, pla-
cebo-controlled, parallel-group, double-blind trial at the Leiden University Medical 
Center after approval of the protocol by the ethics review board. All patients gave in-
formed consent. We included 44 patients fulfilling the diagnostic criteria53,63 for defi-
nite (n = 42) or probable (n = 2) IBM according to a previously reported recruitment 
process.63 Inclusion criteria included sufficient residual muscle strength to evaluate 
changes, absence of  risk factors for MTX-induced toxicity, no use of immunosuppres-
sive therapy for at least 6 weeks before the study, no previous use of MTX, no use 
of medication interfering with MTX pharmacokinetics or pharmacodynamics, and 
absence of severe dysphagia interfering with oral medication use.  
Baseline studies were carried out 2 weeks before therapy initiation. Clinical evalua-
tions comprised quantitative muscle power testing (QMT) by handheld myometry 
assessing the maximum voluntary contraction69 and manual muscle testing (MMT) 
by the six-point Medical Research Council68 (MRC) scale. Activity limitations were 
evaluated according to the Barthel index,65 Brooke’s Grading System67 and the River-
mead Mobility Index.66 Laboratory studies included serum creatine kinase (CK) activ-
ity levels. 
One investigator (UB) tested baseline muscle strength. The mean scores of each of 14 
muscle groups tested three times with QMT were added to a QMT sum score. MMT 
measurements resulting in a sum score were performed on 32 muscle groups.   
Trial medication was distributed by the hospital pharmacy. Patients were randomly 
assigned, using a computer-generated schedule, to receive either MTX or an identical-
appearing placebo. The randomization schedule used random numbers in permuted 
blocks of 4. The code was concealed by the pharmacy and broken after assessment of 
all patients. 
A 48-week treatment period started with a dose of 5 mg per week, each six weeks 
increased by 5 mg up to 20 mg. To enhance blinding, all patients were requested to 
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decrease their 20 mg dosage by 2.5 mg without explanation after routine laboratory 
evaluations for 3 months. After blood assessments, the dosage was restored to 20 mg 
per week. 
A blinded assessor (JV) monitored patients with regard to treatment schedules, 3-
month routine laboratory evaluations, including serum CK activity, and adverse 
events. Another blinded assessor (UB) evaluated the QMT and MMT measurements, 
and patients’ opinion concerning the state of muscle weakness (scored as progres-
sion, stabilization or improvement) at 22 and 48 weeks after treatment initiation and 
activity limitations at 48 weeks. Patients who discontinued study treatment were im-
mediately assessed.  
The primary study outcome measure was the difference in mean change from baseline 
of the QMT sum scores between the two study groups. Secondary outcome measures 
were the differences in MMT sum scores, the three activity scales, the patient’s sub-
jective opinion of the muscle strength and the changes in serum CK activity levels.
To detect a difference of 100 Newtons (N) in mean changes or a clinically important 
stabilization 44 patients were required (power = 0.80; α = 0.05) according to the fol-
lowing assumptions: an annual decline in muscle strength in IBM patients of 5%, a 
mean change in QMT sum score of 100 N over 48 weeks for placebo and zero for MTX 
with a standard deviation of 100 N and a dropout rate of 25%.       
An intention-to-treat analysis with carry forward of last assessments in case of miss-
ing data was performed. Statistical tests were two-sided. The mean changes in muscle 
strength sum scores were compared by mixed-model analysis of variance, with the 
sum score as dependent variable, randomized treatment as factor, time as covariate 
and by treatment-time interaction, and by independent-samples t-test.  
results
Twenty-one patients were allotted to MTX and 23 to placebo (Figure 1). Baseline char-
acteristics were similar for the two groups (Table). Significantly more patients on MTX 
discontinued treatment (8 vs. 1 for placebo, p = 0.008, Fisher ’s exact test), mostly 
because of adverse events. The mean weekly dose of MTX was 14.0 mg in all treated 
patients and 14.6 mg in those who completed the entire study.
Primary outcome
Mean QMT sum scores declined both for MTX (−0.2%) and placebo (−3.4%). This 
difference was not significant (p = 0.3; 95% confidence interval [CI] −2.5% to +9.1% 
for difference). A per-protocol analysis including only those patients who fully com-
pleted the study also showed no difference: +0.9% for MTX and −2.7% for placebo (p 
= 0.3; 95% CI = −3.3% to +10.7%) (Figure 2).
Except for CK values, none of the other study parameters showed a significant differ-
ence between MTX and placebo. MMT sum scores decreased in both groups, −0.5% 
for MTX and −2.0% for placebo (p = 0.2; 95% CI = −1.0% to +3.9% for difference). In 
the per-protocol analysis MMT sum score changes were −2.2% for MTX and −3.8% 
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for placebo (p = 0.4; 95% CI = −2.3% to +5.4%) (see Figure 2). The scores on activity 
scales did not change from baseline (see Table). Two patients had a subjective im-
provement in strength at 48 weeks, both from the placebo group. Twelve patients, 5 
from the MTX group, noticed no change; others felt they had deteriorated. Serum CK 
values fell in both groups, but more so in the MTX group, notably in the first treat-
ment period: from 676 to 274 U/l for MTX and from 725 to 690 U/l for placebo (p = 
0.01; 95% CI = −732 to −102 for difference).
Figure 1  Flow chart of assessed patients with IBM and progress during treatment with methotrex-




not meeting inclusion criteria (n=12)
refused to participate (n=20)
other reasons (n=9)






















Age 68 (±8)       69 (±7)
Female 6       5
Duration of symptoms (years) 9 (±5)       11 (±7)
Other autoimmune disorders 6       6
Discontinuation of immunosuppressive therapy prior to 
baseline studies
2       2
Sum score by hand-held dynamometry (N) 2533 (±800) 2492 (±844)
Sum score by MRC 255 (±34)  247 (±37)
Wheelchair bound 1       1
CKa (U/l) 676 (±830) 725 (±761)
     Median     
     Minimum-maximum
Activity score
     Barthel index (0-20)
     Rivermead mobility index (0-15)






       511
      148-3035
      
      18 (±3)
      12 (±3)
      6 (±3)
Mean ±SD
a Normal value < 200 U/l
CK = creatine kinase; MRC  = Medical Research Council; N = Newton.
Adverse events
Four patients in the MTX group and 1 patient in the placebo group required dose re-
ductions because of adverse events. One patient on placebo discontinued trial medica-
tion because of progressive muscle weakness. Seven patients on MTX discontinued trial 
medication because of nausea (n = 3), hair loss (n = 2), arthralgia (n = 2), and progressive 
muscle weakness (n = 1).
discussion
We investigated whether immunosuppression with MTX could slow down decline of 
muscle strength in IBM over a near-year treatment period. Randomization was adequate, 
as study groups were similar with regard to important baseline characteristics.
We failed to find a significant difference between MTX and placebo, possibly because of 
the lower than expected decline in the placebo group (3.4% in stead of 5%), a greater than 
anticipated variability in QMT results of patients (250 Newton in stead of 100 Newton), 
and a greater than expected dropout rate because of adverse events (8/21). As a result the 
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post hoc power of the study turned out to be only 23%. We had based our conservative 
estimation of disease progression on the only available data on the natural course of IBM 
showing a decline in muscle strength of 1.4% per month (range 0.5 to 2.8%).44 
Muscle strength testing according to both the QMT and MMT sum scores showed a trend 
towards slowed decline of muscle weakness in the MTX group. Activity scales and pa-
tients’ own assessments did not show a difference among treatment groups. The only 
statistically significant finding of predefined outcome measures was a decrease in serum 
CK activities in the MTX group. 
Because of the low post hoc study power, as exemplified by the wide 95% confidence in-
terval for treatment difference, we cannot completely rule out a clinically relevant effect 
of MTX, although this seems unlikely. To unequivocally demonstrate such a beneficial 
effect, 110 patients per treatment arm would be required over a 48 week-period or 28 
patients per treatment arm over 2 years. The large patient groups necessary for the first 
option would require a multinational trial. The second option is obviously unattractive. 
Furthermore, the relatively high incidence of adverse events make MTX a less attractive 
treatment option in this disorder.   
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Figure 2  Mean (±SE) changes in percent from baseline in quantitative muscle testing scores (left) 
and manual muscle testing scores (right) after 22 and 48 weeks of treatment with metho-
trexate (MTX) (solid diamonds) or placebo (solid quares) for intention to treat design 
(above) and per-protocol design (below). 
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The decrease in serum CK activity levels during treatment with MTX suggests inhibition 
of inflammation and is in line with other findings showing a decrease of CK activity and 
of signs of inflammation in biopsies after treatment with intravenous immunoglobulin or 
prednisone.91,92,92
In conclusion, the findings of the present study do not support the use of MTX in IBM. 
The clinical course in the placebo group may provide a useful basis for future studies in 








In 1978 inclusion body myositis (IBM) was recognized as a separate entity. Thereafter, the 
disorder became known as a slowly progressive mixed inflammatory and degenerative 
myopathy of the elderly, especially of men, with proximal or distal muscle weakness with 
absence of (sustained) improvement with anti-inflammatory therapy. At the beginning 
of the present study epidemiological data were scanty, the clinical features were not re-
garded distinctive enough for the disease to be of diagnostic aid for a definitive diagnosis, 
the aetiology of IBM was unclear with controversy with regard to the role of autoimmune 
mechanisms, and the possible effects of long-lasting anti-inflammatory treatment had not 
been investigated.       
summary
At first, we described the prevalence of inclusion body myositis (IBM) in the Netherlands 
(Chapter II). On July 1st, 1999, the prevalence was estimated at no less than 4.9 patients 
per million inhabitants with large local differences between provinces of the Netherland 
(0-12 patients per million inhabitants) and with men being affected twice as frequently as 
women. The incidence rate increased trend-wise since the 1980s. Patient’s delay was simi-
lar for both sexes, but doctor’s delay was longer for women. The most frequent diagnoses 
made before a diagnosis of IBM was made were polymyositis and motor neuron disease. 
The age at death was similar for a small group of IBM patients compared to the mean life 
expectancy of the general population. 
The study of the clinical features and clinical course of IBM (Chapter III) primarily con-
cerned the way the disorder had evolved in retrospect from its first symptoms until cross-
sectional examination. At the latter time, symptoms, signs, function scales as well as se-
rum creatine kinase (sCK) activities were assessed in order to redefine more or less typical 
characteristics of the disease. According to our study, time of onset of symptoms was gen-
erally after the age of forty. Symptoms at onset could be linked to weakness of the quad-
riceps muscles, especially in men, and less frequently to weakness of the finger flexors or 
pharyngeal muscles. Weakness was progressive with a highly variable intra- and inter-
individual progression rate. The direction in which muscle weakness spread from one 
muscle group to another was erratic. Progression of weakness was faster when symptom 
onset was over the age of 56 as compared to onset before this age. Complete wheel-chair 
dependency was rare and wheel chairs were primarily used to prevent falls. Patients did 
not have to discontinue their employment as a result of IBM and had relatively favorable 
scores on commonly used function scales. Ankylosis was a common finding, in particular 
extension of the fingers, but could be helpful in performing certain skilful movements. 
A specific pattern of muscle weakness distribution was observed: ventral muscles were 
more frequently and severely affected than dorsal muscles, and girdle muscles were rela-
tively spared. 
Low-frequency repetitive nerve stimulation was applied in order to investigate the 
function of the neuromuscular synapse (Chapter IV). All studies showed normal com-




In IBM patients a high frequency of (additional) autoimmune disorders was observed 
(Chapter V). In addition, compared to controls patients with IBM had a high frequency of 
HLA-antigens of the autoimmune prone HLA-A1-B8-DR3-DR52-DQ2 complex. This high 
frequency could be related to IBM alone and not to the presence of (other) autoimmune 
disorders. The presence of HLA-A1 was associated with an earlier onset of symptoms. 
HLA-DR53 was almost absent in IBM patients. 
Lastly, a randomized placebo controlled trial is described (Chapter VI) in which patients 
were randomly allocated to an approximately one-year treatment with oral methotrexate 
(MTX) or placebo to assess the tolerability of MTX and its possible capacity to slow down 
disease progression. MTX was poorly tolerated as evidenced by the high percentage of 
patients who discontinued treatment. In addition, no important effect on weakness pro-
gression could be demonstrated, although sCK activity levels dropped with MTX treat-
ment but not with placebo.   
discussion
The exact frequency of IBM is unknown. Epidemiological data are needed to provide 
insight in the difficulties at hand with establishing the diagnosis. They are also needed 
to understand the mechanism of the disease. Finally, they are necessary to estimate the 
feasibility of a therapeutic trial. This is more important in a relatively new disorder, which 
is ill defined. Our study methods allowed us to estimate the minimal prevalence of IBM 
in the Netherlands (Chapter II). The increase in the number of patients diagnosed during 
the last decades, the regional differences in prevalence, and the substantial doctor’s de-
lay in diagnosing IBM suggest an underestimation of the true prevalence. The observed 
rise in the incidence of IBM most probably reflects a growing familiarity with the disease 
particularly among neurologists and pathologists, which leads to earlier diagnosis and re-
vision of incorrect diagnoses. An additional, but minor factor with regard to the rising in-
cidence could be the increase of the elderly population, as IBM is a disease of the elderly. 
Many patients of the population screened for our studies had a clinical picture strongly 
suggestive of IBM but did not fulfill all required histopathological criteria. Therefore, the 
establishment of the diagnosis of IBM by histopathological criteria, also bearing the risk 
of a false negative diagnosis due to sampling error, may contribute to underestimation 
of the frequency of the disorder. As autoimmune disorders are assumed to have risen in 
frequency according to figures of the last decades, unknown environmental factors may 
have influenced the figures as well.93 The only presently available prevalence figures are 
those of the city of Göteborg (33 x 10-6 inhabitants),44 those of the present study from the 
Netherlands (≥ 4.9 x 10-6 inhabitants) and figures from Western Australia (9.3 x 10-6 inhab-
itants)94 and Connecticut (10.7 x 10-6 inhabitants)60 published afterwards. Remarkably, 
no deaths were mentioned in the last paper during an eight-year review period, raising 
suspicion on whether correction for death subjects was applied in calculating their preva-
lence figure. 
Based on the available figures a higher prevalence of IBM with increasing latitudes is a 
possibility and, therefore, prevalence figures in (sub)tropical areas and non-Caucasian 
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populations remain of interest. The reason for the higher susceptibility of men for the 
disease remains mysterious. The longer delay in diagnosing a female patient with IBM 
compared to a male patient is also of interest, as females tend to seek medical assistance 
earlier than men.95 A factor that may have played a role with regard to the latter could be 
the tendency of women to present with less obvious symptoms, such as swallowing dif-
ficulties and slight weakness of the finger flexors, which are not uncommonly attributed 
to age. In contrast, men most often present with quadriceps weakness and among them a 
large proportion is still in their forties as well (Chapter III). Furthermore, atrophy is more 
obvious in men as a result of different ratios of muscle bulk and subcutaneous fat in men 
and women. 
As it appears from our studies, IBM patients as a group have an extraordinary pattern of 
muscle weakness: ventral muscles are more severely and frequently involved than dorsal 
muscles, and girdle muscles are mostly spared. We do not have an unequivocal explana-
tion for this distribution of the muscle weakness. Functionally, ventral muscle groups for 
example, the foot extensors on walking and the quadriceps on walking down the stairs 
undergo more stretch during active contraction. Such stretch has previously been consid-
ered to damage the muscles.96 Evidently, this consideration is not applicable to the upper 
extremities. 
Making a diagnosis of IBM is difficult, especially at an early stage of the disease, when 
“typical” clinical clues may be lacking or may not be recognized. The exceptionally fre-
quent involvement of finger and wrist flexors is striking but cannot be regarded as typi-
cal as it is also commonly present in for example myotonic dystrophy. However, in the 
context of a non-hereditary presentation with a slow, most often asymmetric progression 
of muscle weakness at an advanced age, the finding of finger flexor weakness is strong in 
favor of a diagnosis of IBM.   
The presence of HLA-A1 was related to an earlier age of onset (Chapter IV). In this study, 
a younger age at onset was associated with a lower rate of progression of the disease. 
Therefore, the HLA system not only plays a role in susceptibility, but is likely to influence, 
although indirectly, the rate of progression through HLA-A1 (Chapter V).   
One of the factors contributing to muscle fiber destruction is likely cytotoxicity exerted 
by CD8-positive T-cells, although the antigens responsible for this reaction are unknown. 
The fact that IBM, as many other autoimmune disorders, is associated with HLA-B8-DR3 
and the fact that other autoimmune disorders frequently co-occur with IBM provides 
support for the concept of IBM being an immune-mediated disorder. 
The role of synaptic dysfunction as a contributory factor for muscle weakness in IBM was 
found to be negligible.
The statement made by many of our IBM patients “I am weak but not ill” is underlined 
by the problems we experienced with regard to our therapeutic trial. Many patients were 
not prepared to experience even minor side effects despite the perspective of a possibly 
slower deterioration of their muscle weakness. The number of patients that discontinued 
treatment was much higher than in a comparable trial concerning rheumatoid arthritis, 
a disease in which patients typically suffer pain or malaise.90 An open, randomized pilot 
study in 11 patients comparing 12-month treatment with 7.5 mg MTX a week alone and 
a similar treatment preceded by seven days of anti-T-lymphocyte immunoglobulin (ATG) 
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showed an increase in mean muscle strength in the ATG group (n = 6) by 1.4% compared 
to a decrease in the MTX group (n = 5) of 11.1%.97 The sCK activity decreased after one 
week in the ATG-MTX group but did not change at all in the MTX group. The authors of 
this report concluded that a follow up study with ATG was worthwhile. The deterioration 
in the MTX group in this study was much larger than in our study. The small sample size, 
the different composition of the muscle strength sum score (for example, differences in 
myometer, number and type of measured muscle groups, number of investigators), bias 
due to the study type make comparison with our study difficult. Besides, the MTX dosage 
was possibly too low to act anti-inflammatory, as the sCK values remained unchanged. 
Another randomized placebo controlled pilot study in 30 patients showed no differences 
between treatment groups after six months of treatment with beta-interferon-1a (60 mi-
crogram IM/week) or placebo.98 
An open controlled pilot study with etanercept in nine patients with a mean treatment 
time of 17 months did not show a significant effect in muscle strength sum scores as 
well.
Why did MTX not result in an increase in strength or a slowing of the progression of the 
disease in our study? There is no simple explanation, but several factors, both host- and 
agent-related could have played a role. Weak muscles in which the vast majority of muscle 
fibers has vanished are unlikely to show substantial muscle fiber regeneration. In our study 
with a mean disease duration of more than nine years, an increase in strength was to be 
expected only in muscles with active inflammation but with minor fiber reduction. 
Muscle strength deterioration tended to stabilize with higher dosages of MTX in the 2nd 
half of the study. This could mean that we have treated patients too long with too low 
dosages. If higher dosages of MTX would be effective, it remains questionable whether 
such dosages would be tolerated by the patients and whether the effect would be clini-
cally relevant.     
PersPectives for tHe future
In the forthcoming time randomized trials should be done at a time when the expected 
effect would still be optimal, that is, before extensive muscle wasting has occurred. In this 
respect, an early diagnosis is indispensable. Larger patients groups are needed to be able 
to perform randomized trials of short duration with reliable power. Besides, the natural 
history of the disease can be studied prospectively by making an early diagnosis. To en-
able an early diagnosis on a wide scale new consensus criteria are necessary. For prag-
matic reasons these criteria should have a clinical rather than a histopathological basis. 
Our study shows the necessity for new criteria: 21 patients, approximately a quarter of all 
patients with clinical features of IBM, were not diagnosed as such because of the lack of 
one or more agreed histopathological criteria. We strongly suspect that our criteria were 
insufficiently sensitive.
The role of the pathologist will probably change from one indispensable for the diagnosis 
to one offering support to the diagnosis. Whatever the case, histopathological research 
will remain important for study and understanding of the pathogenesis of the disease. 
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The debate of whether the origin of the disease is immune-mediated, hence potentially 
treatable, or degenerative Alzheimer-like in origin, therefore, not or barely treatable tends 
to take a turn in favor of the first option. Recent publications support the concept of an 
immune-mediated and stress-related imbalance of the protein synthesis in the muscle 
fiber. This could mean that highly specific immunological intervention trials remain pos-










Na 1978, nadat inclusion body myositis (IBM) algemeen erkend was als aparte ziekte 
entiteit, werd de ziekte gaandeweg beschouwd als een langzaam progressieve gemengd 
inflammatoire en degeneratieve myopathie van de oudere, vooral van de man, die ge-
paard gaat met proximale en distale spierzwakte en het ontbreken van een aanhoudende 
verbetering bij anti-inflammatoire behandeling. Bij de aanvang van dit onderzoek waren 
epidemiologische gegevens schaars, werden klinische verschijnselen niet als voldoende 
onderscheidend beschouwd om van voldoende nut te zijn bij het stellen van een zekere 
diagnose, was de etiologie van IBM onduidelijk, waren er controverses ten aanzien van 
de rol van auto-immuun mechanismen, en waren de mogelijke effecten van zeer langdu-
rige immunosupressieve behandeling niet onderzocht.
samenvatting
Allereerst beschreven wij een onderzoek naar de prevalentie van IBM in Nederland 
(hoofdstuk II). Op 1 juli 1999 werd deze geschat op minstens 4,9 patiënten per miljoen 
inwoners, met grote provinciale verschillen (0-12 patiënten/miljoen inwoners) en waarbij 
mannen tweemaal zo vaak waren aangedaan als vrouwen. Vanaf de periode rond 1980 
volgde de incidentie een stijgende trend. De “patient’s delay” was gelijk voor beide ge-
slachten, maar de “doctor’s delay” was langer voor vrouwen. De meest frequent gestelde 
incorrecte diagnosen voorafgaande aan de diagnose IBM waren polymyositis en motor 
neuron ziekte. De leeftijd bij overlijden van een kleine groep IBM patiënten was verge-
lijkbaar met die van de gemiddelde Nederlander.
Het onderzoek naar de klinische verschijnselen en het klinische beloop van IBM 
(hoofdstuk III) was in de eerste plaats gericht op de manier waarop de ziekte zich 
retrospectief gezien ontwikkelde vanaf de eerste klacht tot het moment van het dwars-
doorsnede onderzoek. Op dat moment werden klachten, symptomen, functie scha-
len en de serum creatinine kinase (sCK) activiteit bepaald om zo in tweede instantie 
de min of meer typische kenmerken van de ziekte te kunnen (her)beoordelen. Bij de 
patiënten in dit onderzoek debuteerde de ziekte na het veertigste levensjaar. De eer-
ste klachten konden, vooral bij mannen, worden toegeschreven aan zwakte van de 
quadriceps en minder vaak aan zwakte van de vingerflexoren en de faryngeale spie-
ren. De spierzwakte was progressief, waarbij de snelheid van progressie een grote 
intra- en interindividuele spreiding toonde. De manier waarop zwakte zich van de ene 
spiergroep naar de andere verspreidde verliep niet volgens een consistent patroon. 
De ziekteprogressie was sneller bij een ziekte debuut boven de leeftijd van 56 jaar dan 
daaronder.Volledige rolstoelafhankelijkheid was zeldzaam en het gebruik van de rol-
stoel had vooral tot doel vallen te voorkomen. Patiënten hoefden hun baan niet op te 
geven als gevolg van hun ziekte en hadden relatief gunstige scores op functieschalen. 
Contracturen werden frequent gevonden, vooral extensiecontracturen aan de vingers, 
maar bleken in het geval van de vingers van nut te zijn bij het gebruik van diezelfde 
verzwakte vingers. Wij vonden een vrij consistent patroon van spierzwakte verdeling: 




Laag frequente repetitieve stimulatie werd toegepast om de functie van de neuromus-
culaire synaps te onderzoeken (hoofdstuk IV). Een abnormaal decrement van de sa-
mengestelde spieractiepotentiaal werd niet gevonden, zodat wij geen aanwijzingen 
vonden voor een afwijkende neuromusculaire transmissie. 
Bij onze IBM patiënten werd een opvallend groot aantal bijkomende auto-immuun-
ziekten geconstateerd (hoofdstuk V). Patiënten met IBM hadden daarnaast, vergeleken 
met controle personen, een hoge frequentie van antigenen uit het tot auto-immuun-
ziekte predisponerend HLA-A1-B8-DR3-DR52-DQ2 complex. Deze hoge frequentie 
kon worden toegeschreven aan IBM alleen, en niet aan de aanwezigheid van (andere) 
auto-immuunziekten. De aanwezigheid van het HLA-A1 antigeen was geassocieerd 
met een eerder debuut van de klachten. HLA-DR53 was vrijwel afwezig bij IBM pa-
tiënten.
Tenslotte werd een gerandomiseerde placebo gecontroleerde klinische trial beschreven 
(hoofdstuk VI) waarbij patiënten gedurende bijna een jaar werden behandeld met me-
thotrexaat (MTX) per os of een placebo om de tolerantie voor MTX en de mogelijke ef-
fectiviteit van MTX als vertrager of stabilisator van het ziekteproces te bepalen. Gezien 
het hoge percentage uitvallers werd MTX slecht verdragen. Daarbij kon geen belang-
rijk effect op de ziekte progressie worden gemeten, hoewel de sCK activiteitswaarden 
afnamen bij behandeling met MTX, maar niet in de placebogroep. 
discussie
De exacte prevalentie van IBM is niet bekend. Epidemiologische gegevens zijn nodig 
om inzicht te krijgen in de problemen die zich voordoen bij het tot stand komen van 
de diagnose. Ook zijn zij nuttig bij het onderzoek naar de pathogenese van de ziekte. 
Tenslotte zijn zij onmisbaar om de haalbaarheid van elke therapeutische trial in te kun-
nen schatten. Dit geldt te meer voor een relatief nieuwe en dus onvoldoende omschre-
ven ziekte-entiteit. Met onze onderzoeksmethoden konden wij een schatting maken 
van de minimale prevalentie van IBM in Nederland (hoofdstuk II). Het toenemende 
aantal gediagnosticeerde patiënten in de laatste decaden, de regionale verschillen in 
prevalentie, en het niet onaanzienlijke “doctor ’s delay” bij het stellen van de diagnose 
suggereren een onderschatting van de werkelijke prevalentie. De geconstateerde stij-
gende incidentie van IBM weerspiegelt waarschijnlijk de toenemende bekendheid met 
de ziekte onder vooral neurologen en pathologen, die leidt tot het eerder stellen van 
de juiste diagnose of reviseren van een foute diagnose. Een bijkomende, doch beperkte 
factor in de stijgende incidentie kan de toenemende vergrijzing van de Nederlandse 
bevolking zijn, omdat IBM vaker voorkomt op oudere leeftijd. Het vaststellen van de 
diagnose op grond van histopathologische criteria, waarbij uiteraard ook “sampling er-
ror” kan voorkomen, draagt vermoedelijk bij aan een onderschatting van de frequentie 
van IBM, aangezien er bij de screening van onze onderzoekspopulatie veel patiënten 
waren met een voor de ziekte suggestief klinisch beeld die niet voldeden aan alle af-
gesproken histopathologische criteria. Omdat op basis van prevalentie gegevens aan-
genomen wordt dat de frequentie van auto-immuunziekten de laatste decaden aan 
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het stijgen is zouden onder andere ook onbekende omgevingsfactoren een rol kunnen 
spelen.93 Tot op heden blijven de enige beschikbare prevalentie cijfers die van Gothen-
burg (33 x 10-6 inwoners),44 die van dit onderzoek in Nederland (≥ 4,9 x 10-6 inwoners) 
en later gepubliceerde cijfers uit West Australie (9,3 x 10-6 inwoners)94 en Connecticut 
(10,7 x 10-6 inwoners).60 Merkwaardigerwijs worden in het laatste onderzoek met een 
retrospectieve observatie periode van acht jaar geen sterftegevallen vermeld zodat het 
vermoeden rijst dat hiervoor niet gecorrigeerd is. 
Op basis van de beschikbare gegevens kan een stijgende prevalentie in de richting 
van de poolcirkels niet worden uitgesloten en daarom blijven prevalentie gegevens 
uit (sub)tropische regionen en over niet-kaukasische populaties interessant. Het vaker 
vóórkomen van de ziekte bij mannen blijft opmerkelijk. De langere duur tot het stel-
len van de diagnose bij vrouwen in vergelijking tot mannen is eveneens bijzonder, 
daar vrouwen in het algemeen eerder geneigd zijn zich bij klachten te wenden tot een 
arts.95 Een factor hierbij kan zijn dat vrouwen met IBM vaker debuteren met lastiger 
te interpreteren klachten, zoals problemen met doorslikken of subtiele zwakte van de 
handen, die wellicht eerder worden toegeschreven aan de leeftijd. De meeste mannen 
daarentegen debuteren met quadriceps zwakte; daar komt bij dat een groot deel van 
hen nog tussen de 40 en 50 jaar oud is (hoofdstuk III). Tenslotte is atrofie beter zichtbaar 
bij mannen dan bij vrouwen ten gevolge van de verschillen in ratio van spiermassa 
versus subcutaan vet tussen mannen en vrouwen.
Uit ons onderzoek blijkt dat IBM patiënten een bijzondere verdeling van de spier-
zwakte hebben: ventrale spieren zijn meer en vaker aangedaan dan dorsale terwijl de 
gordelregio relatief gespaard blijft. Wij hebben geen verklaring voor deze verdeling. 
Functioneel zijn ventrale spieren vaak meer onderhevig aan verlenging tijdens actieve 
aanspanning zoals de quadriceps bij het aflopen van een helling of trap of de voethef-
fers bij iedere stap; voor de armen is deze overweging niet evident. Dergelijke rek is 
wel eens verondersteld schade aan de spier toe te brengen.96              
Duidelijk mag zijn dat het stellen van de diagnose IBM lastig is, vooral in de beginfase, 
waarin “typische” klinische aanwijzingen kunnen ontbreken of niet herkend worden. 
Het uitzonderlijk vaak aangedaan zijn van de vinger- en polsflexoren is opvallend, 
maar niet typisch, daar dit fenomeen ook frequent wordt aangetroffen bij bijvoorbeeld 
myotone dystrofie. Toch kan gezegd worden dat de aanwezigheid van zwakte van de 
vingerflexoren in de context van sporadisch voorkomen, gevorderde leeftijd en trage, 
vaak asymmetrische progressie een sterk argument is voor de diagnose IBM. Dit argu-
ment wordt nog versterkt door het tevens voorkomen van zwakte van vooral ventraal 
gelegen spieren. 
De aanwezigheid van het HLA-A1 antigeen was gerelateerd aan een vroeger debuut 
van de klachten (hoofdstuk IV). Bij een jongere debuutleeftijd was de snelheid van de 
ziekte progressie in dit onderzoek lager (hoofdstuk III). Het is daardoor aannemelijk 
geworden dat het HLA systeem niet alleen een rol speelt bij de ontvankelijkheid voor 
de aandoening, maar ook via het HLA-A1 op indirecte wijze de snelheid van progressie 
beïnvloedt.
Een van de factoren die een rol spelen bij de spiervezel destructie lijkt een cytotoxische 
reactie gemedieerd door CD8-positieve T cellen, hoewel antigenen verantwoordelijk 
voor dit proces tot op heden niet zijn gevonden. Het feit dat IBM, net als veel auto-
immuunaandoeningen, is geassocieerd met HLA-B8-DR3 plus het feit dat IBM vaak 
vergezeld wordt door (andere) auto-immuunaandoeningen vormen een verdere steun 
voor het concept dat IBM een immuuungemedieerde aandoening zou zijn.
Op grond van neurofysiologisch onderzoek is aannemelijk geworden dat de neuro-
musculaire overgang geen belangrijke rol speelt bij de spierzwakte van IBM patiënten 
(hoofdstuk V).
Het gezegde van vele IBM patiënten “ik ben zwak, maar niet ziek” werd onderstreept 
door de problemen die ondervonden werden bij de klinische trial (hoofdstuk VI). Veel 
patiënten vonden zelfs maar geringe bijwerkingen niet opwegen tegen het vooruit-
zicht van een mogelijke vertraging van de ziekte progressie. Het aantal patiënten dat 
de behandeling staakte was dan ook veel hoger dan in vergelijkbare trials bij reuma-
toïde artritis,90 een ziekte waarbij patiënten als regel pijn of malaise ervaren, of beide. 
Na afronding van onze trial werden twee andere interventiestudies gepubliceerd. De 
eerste, een open, gerandomiseerde “pilot study” bij 11 patiënten met een follow-up 
van 12 maanden, waarbij MTX (7,5 mg/week) werd vergeleken met hetzelfde regime 
MTX voorafgegaan door een zevendaagse behandeling met anti-T-lymfocyt immuno-
globuline (ATG), toonde een toename in de gemiddelde spierkracht in de ATG-MTX 
groep (n = 6) met 1.4%, terwijl de MTX groep (n = 5) met 11.1% achteruit ging. De sCK 
activiteit daalde in de ATG-MTX groep na een week maar bleef onveranderd in de MTX 
groep.97 De auteurs achtten een vervolgonderzoek met ATG zinvol. De verslechtering 
in hun MTX groep was groter dan in ons onderzoek. De geringe omvang van de groe-
pen, de andere samenstelling van de somscore (waaronder verschillen in type myome-
ter, aantal en aard van de gekozen spiergroepen, aantal onderzoekers) voor de spier-
kracht en “bias” ten gevolge van het open karakter van de studie maken vergelijking 
met onze studie moeilijk. Ook was de dosis MTX mogelijk onvoldoende om ontsteking 
te remmen gezien de onveranderde sCK activiteit. Een andere placebogecontroleerde 
gerandomiseerde “pilot study” bij 30 patiënten toonde geen verschil in spierkracht aan 
tussen de groepen na zes maanden behandeling met beta-interferon-1a (60 microgram 
IM/week) of placebo.98 Een open gecontroleerde studie met etanercept bij negen pa-
tiënten gedurende een gemiddelde onderzoeksperiode van 17 maanden resulteerde 
niet in een significant verschil in totale spierkracht somscores.
Hoe komt het dat MTX in ons onderzoek niet resulteerde in een toename van kracht 
of vertraging van progressie?  Hierover is geen eenduidige uitspraak te doen, maar 
er zouden zowel patiënt- als medicamentgerelateerde redenen kunnen zijn. Zwakke 
spieren waarvan een groot deel van de spiervezels verdwenen is, zijn uiteraard minder 
in staat tot substantiële regeneratie. In dit onderzoek, met een gemiddelde ziekteduur 
van ten minste negen jaar, is daardoor waarschijnlijk alleen een merkbaar effect te ver-
wachten in spieren met actieve ontsteking, maar slechts beperkt verval. De trend van 
spierkracht afname veranderde in de richting van stabilisatie bij behandeling met ho-
gere doses MTX in het tweede deel van het onderzoek. Dit zou kunnen betekenen dat 
wij te lang met te lage initiële doses behandeld hebben. Ook als hogere doses effectief 
zouden zijn, is het maar de vraag of de patiënten deze doses verdragen en of het effect 




In de komende tijd zouden interventiestudies gedaan moeten worden op het moment 
dat het te verwachten effect nog optimaal is en dus niet verdoezeld wordt door uitge-
breid spierverval. Hiervoor is een vroege diagnose onmisbaar. Om interventie studies 
van een kortere duur te kunnen doen met een goede “power” zijn grotere patiënten 
populaties nodig. Door de diagnose in een vroeg stadium te stellen kan bovendien het 
natuurlijk ziektebeloop prospectief worden vervolgd. Om de diagnose op grote schaal 
vroeg te kunnen stellen is consensus nodig over nieuwe criteria. Die criteria zouden om 
pragmatische redenen in eerste instantie een klinische, niet een pathologische, insteek 
moeten hebben. 
De noodzaak van nieuwe criteria voor prospectief onderzoek wordt duidelijk uit onze 
studie: 21 patiënten, grofweg een kwart van het totale aantal, die het klinische beeld 
vertoonden van IBM, kregen niet de diagnose als gevolg van het ontbreken van één of 
meerdere afgesproken histopathologische criteria. Wij hebben het sterke vermoeden dat 
de door ons gebruikte criteria onvoldoende sensitief waren. 
De rol van de patholoog zal waarschijnlijk veranderen, waarbij de histopathologie gaat 
dienen ter ondersteuning van de diagnose, maar niet meer als het obligaat diagnosticum. 
Desondanks zal histopathologisch onderzoek wel een belangrijke rol blijven spelen bij 
het onderzoek voor de pathogenese van de aandoening.
De discussie over de vraag of IBM een immuungemedieerde, en dus potentieel behan-
delbare ziekte is, of een degeneratieve, op de ziekte van Alzheimer gelijkende, en dus 
niet of nauwelijks beïnvloedbare ziekte, lijkt zich meer te verplaatsen in de richting van 
de eerste optie. Recent onderzoek99,100 steunt het concept van immuungemedieerde en 
stressgerelateerde verstoring van de eiwitsynthese in de spiervezel. Dit zou kunnen be-
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